[Acute myelogenous leukemia developed at the 26th week of gestation].

Haruko Tashiro, Koichi Umezawa, Michihiko Shirota, Yoko Oka, Ryosuke Shirasaki, Ryuichi Nishi, Akinori Taguchi, Nobu Akiyama, Kazuo Kawasugi, Takuya Ayabe, Naoki Shirafuji

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

We report here a 35-year-old pregnant woman with acute myelogenous leukemia (AML). She was diagnosed with AML (M2) in August 2009, coinciding with the 26(th) week of pregnancy. She underwent a cesarean section at 27 weeks gestation, delivering a very low birth weight male infant (1,066 g). One week later, she received induction chemotherapy with idarubicin and cytarabine. She achieved complete remission after two courses of chemotherapy. The incidence of acute leukemia during pregnancy is low. Chemotherapy after the 2(nd) trimester is not associated with an increased rate of fetal malformation. However, there are some reports that in utero exposure to chemotherapy during any trimester of pregnancy carries a significant risk for an unfavorable outcome including low birth weight, fetal or neonatal death, and intrauterine growth retardation. Decision on the choice of treatment for acute leukemia during pregnancy should be case-dependent. If an infant has grown sufficiently to be viable outside uterus and the patient does not demonstrate a severe bleeding tendency, delivery by cesarean section preceding chemotherapy is one option.

Original languageEnglish
Pages (from-to)18-22
Number of pages5
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume52
Issue number1
StatePublished - Jan 2011

Fingerprint

Dive into the research topics of '[Acute myelogenous leukemia developed at the 26th week of gestation].'. Together they form a unique fingerprint.

Cite this